Author:
Lyu Su Ir,Krey Thaddaeus,Damanakis Alexander I.,Zhao Yue,Bruns Christiane J.,Schmidt Thomas,Popp Felix C.,Quaas Alexander,Knipper Karl,Heise Michael,Marusch Frank,Siech Marco,Mosa Tawfik,Schniewind Bodo,Tepel Jürgen,Hartwig Werner,Prinz Christoph,Rau Bettina M.,Niedergethmann Marco,Kube Rainer,Saada George,Hiller Wolfgang,Settmacher Utz,
Abstract
Abstract
Purpose
Rising incidence of pancreatic ductal adenocarcinoma (PDAC) bind with insufficient therapy options showcases a great medical challenge. Further biomarkers are required to identify patients, who will benefit from more aggressive therapy.
Methods
320 patients were included by the PANCALYZE study group. Cytokeratin 6 (CK6) immunohistochemical staining as a putative marker for the basal-like subtype of PDAC was performed. The correlation between CK6 expression patterns and survival data, as well as various markers of the (inflammatory) tumor microenvironment, were analyzed.
Results
We divided the study population based on the expression pattern of CK6. Patients with a high CK6 tumor expression had a significantly shorter survival (p = 0.013), confirmed in a multivariate cox regression model. CK6-expression is an independent marker for a decreased overall survival (HR = 1.655, 95% CI 1.158–2.365, p = 0.006). In addition, the CK6-positive tumors showed significantly less plasma cell infiltration and more cancer-associated fibroblasts (CAFs) expressing Periostin and SMA.
Conclusions
CK6 could be considered as an independent biomarker for a shorter overall survival. CK6 is a clinically easily accessible biomarker for the identification of the basal-like subtype of PDAC. Therefore, it could be taken into consideration in deciding for the more aggressive therapy regimes. Prospectively, studies addressing the chemosensitive characteristics of this subtype are required.
Funder
Universitätsklinikum Köln
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献